Drug profile · INN
ibandronate sodium
IBANDRONATE SODIUM
ibandronate sodium (IBANDRONATE SODIUM) is a farnesyl diphosphate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — ibandronate sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
ibandronate sodium (IBANDRONATE SODIUM) is a farnesyl diphosphate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Farnesyl diphosphate synthase inhibitor
Primary target: Farnesyl pyrophosphate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ibandronate sodium?
ibandronate sodium (IBANDRONATE SODIUM) is a farnesyl diphosphate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ibandronate sodium?
IBANDRONATE SODIUM is a marketed brand name for ibandronate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ibandronate sodium?
ibandronate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.